What are the recommended treatments for the prophylaxis of migraine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Migraine Prophylaxis Treatment Recommendations

For migraine prophylaxis, first-line medications include propranolol (80-240 mg/day), timolol (20-30 mg/day), amitriptyline (30-150 mg/day), divalproex sodium (500-1500 mg/day), sodium valproate (800-1500 mg/day), and topiramate (100 mg/day). 1

When to Consider Preventive Therapy

Preventive therapy should be initiated when:

  • Migraines occur ≥2 times per month
  • Attacks are prolonged and disabling
  • Quality of life is reduced between attacks 1

The goal of preventive therapy is to achieve at least a 50% reduction in attack frequency, with an adequate trial requiring 6-8 weeks at therapeutic doses to properly assess effectiveness 1.

First-Line Pharmacological Options

Beta-Blockers

  • Propranolol (80-240 mg/day): FDA-approved for migraine prophylaxis with strong evidence supporting its efficacy 1, 2
  • Timolol (20-30 mg/day): Also recommended by the American Academy of Neurology 1

Anticonvulsants

  • Topiramate (100 mg/day): Highly effective for migraine prevention with strong evidence 1, 3
    • Start at 25 mg/day and titrate by 25-50 mg weekly to target dose
    • Has shown significant reduction in monthly migraine days compared to placebo (3.5 days vs 0.2 days) 3
  • Divalproex sodium (500-1500 mg/day) or Sodium valproate (800-1500 mg/day) 1
    • Caution: Avoid in female adolescents and women of childbearing potential due to teratogenic risk 1

Antidepressants

  • Amitriptyline (30-150 mg/day): Effective for migraine prevention 1

Second-Line Options

CGRP Antagonists

  • Erenumab, fremanezumab, or galcanezumab: Strongly recommended for patients with inadequate response to first-line treatments 1
  • Ubrogepant and rimegepant: Newer options with "weak for" recommendation 1

Complementary Approaches

Consider adding these evidence-based complementary treatments:

  • Magnesium supplements: 400-600 mg daily 1
  • Riboflavin: 400 mg daily 1
  • Coenzyme Q10 1
  • Feverfew: May reduce pain intensity and associated symptoms 1, 4

Non-Pharmacological Approaches

Implement these lifestyle modifications for all patients:

  • Regular sleep schedule
  • Consistent meal times
  • Adequate hydration
  • Regular physical activity
  • Stress management techniques
  • Identification and avoidance of personal triggers 1

Evidence-based behavioral interventions include:

  • Cognitive behavioral therapy
  • Relaxation techniques
  • Regular exercise 1, 4

Important Considerations and Monitoring

Medication Overuse Prevention

  • Limit acute medication use to prevent medication overuse headache:
    • NSAIDs ≤15 days/month
    • Triptans ≤10 days/month 1

Special Populations

  • Pregnancy: Use caution with preventive medications; many are contraindicated
  • Cardiovascular risk: Be cautious with beta-blockers in patients with bradycardia or heart block
  • Diabetes: Monitor blood glucose more frequently when initiating new medications 1
  • Obesity: Consider topiramate which may assist with weight loss as a beneficial side effect 1

Monitoring Effectiveness

  • Use a headache diary to track:
    • Frequency and duration of headaches
    • Pain intensity and characteristics
    • Associated symptoms
    • Triggers
    • Medication use and response 1

Treatment Algorithm

  1. Initial Assessment: Determine if patient meets criteria for preventive therapy (≥2 migraines/month, disabling attacks, reduced quality of life)
  2. First-Line Selection: Choose from propranolol, timolol, amitriptyline, divalproex/valproate, or topiramate based on:
    • Comorbidities (avoid valproate in women of childbearing potential)
    • Side effect profile (consider topiramate if weight loss desired)
    • Patient preferences
  3. Titration: Start at low dose and gradually increase to therapeutic range
  4. Evaluation: Assess effectiveness after 6-8 weeks at therapeutic dose
  5. Adjustment: If <50% reduction in attack frequency:
    • Try another first-line agent OR
    • Consider CGRP antagonists as second-line therapy
  6. Complementary Approaches: Add magnesium, riboflavin, CoQ10 as adjuncts
  7. Lifestyle Modifications: Implement consistently throughout treatment

Remember that the target is a 50% reduction in attack frequency, and an adequate trial requires 6-8 weeks at therapeutic doses to properly assess effectiveness.

References

Guideline

Migraine Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Migraine Headache Prophylaxis.

American family physician, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.